Ascendis Pharma A/S plans to sell $150 million of its American depositary shares, each representing 1 ordinary share of the company, in an underwritten public offering.
The company also plans to grant the underwriters an option to buy up to an additional $22.5 million of ADSs.
J.P. Morgan Securities LLC, Bank of America Merrill Lynch and Credit Suisse Securities (USA) LLC are acting as joint book-running managers for the offering.
